ASCENT: Phase 2a, randomized, double-blind, placebo controlled study evaluating safety and immunogenicity of two HIV-1 prophylactic vaccine regimens comprising Ad26. Mos4. HIV and either clade C gp140 or bivalent gp140

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Stieh, DJ; Tomaka, F; Comeaux, CA; Nijs, S; Callewaert, K; Hendriks, J; Euler, Z; Tomaras, GD; Alter, G; Kublin, J; Corey, L; McElrath, J; Swann, E; Robb, M; Michael, N; Marovich, M; Pau, MG; Barouch, DH; Schuitemaker, H

Published Date

  • July 1, 2019

Published In

Volume / Issue

  • 22 /

Start / End Page

  • 98 - 98

Published By

Pages

  • 1

Electronic International Standard Serial Number (EISSN)

  • 1758-2652